000			03515nam a2200421 i 4500
988			_aSpringer_BiomedLife_2019
999			_c115841 _d115841 _x1
001			115841
003			ESmaUEC
005			20230110040239.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190910s2019 gw | s |||| 0|eng d
020			_a9783030187224
024	7		_a10.1007/978-3-030-18722-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC270.8 _b2019 EB
100	1		_aLink, Wolfgang _eautor _9671811
245	1	0	_aPrinciples of cancer treatment and anticancer drug development _cby Wolfgang Link
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_a1 recurso en línea (XIV, 145 páginas) _b45 ilustraciones, 43 ilustraciones a color
336			_aTexto _btxt _2rdacontent
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aPreface -- Acknowledgements -- Contents -- Abbreviations -- Introduction -- Cancer Therapy -- Cancer drug resistance -- Drug Discovery and Development -- Economic and social implications of modern drug discovery. Index.
520	3		_aThis book explains how current medicines against cancer work and how we find new ones. It provides an easy-to-understand overview of current options to treat patients with cancer, which includes Surgery, Radiation therapy, Chemotherapy, Targeted therapy and Immunotherapy. The efficiency of all these treatments is limited by the capacity of cancer cells to escape therapy. This book explains the mechanisms of anti-cancer drug resistance and strategies to overcome it. The discovery and development process of a new drug is detailed beginning with the identification and validation of a therapeutic target, the identification of an inhibitor of the target and its subsequent preclinical and clinical development until its approval by regulatory authorities. Particular emphasis has been given to specific aspects of the development process including lead generation and optimization, pharmacokinetics, ADME analysis, pharmacodynamics, toxicity and efficacy assessment, investigational new drug (IND) and new drug application (NDA) and the design of clinical trial and their phases. The book covers many aspects of modern personalized oncology and discusses economic aspects of our current system of developing new medicines and its impact on our societies and on future drug research. The author of this book, Dr. Link counts with more than 20 years of experience in biomedical research reflected in numerous publications, patents and key note and plenary presentations at international conferences. Interested readers, students and teachers should read this book as it provides a unique way to learn/teach about basic concepts in oncology and anti-cancer drug research.
650		7	_2embne _9139308 _aCáncer _xTratamiento
650		7	_2embne _9139308 _aCáncer _xQuimioterapia
650		7	_2embne _9139308 _aCáncer _xInmunoterapia
776	0	8	_iPrinted edition: _z9783030187217
776	0	8	_iPrinted edition: _z9783030187231
776	0	8	_iPrinted edition: _z9783030187248
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-18722-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _eel _zSI